We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Liposomal amphotericin B and leishmaniasis: dose and response.
- Authors
Sundar, Shyam; Chakravarty, Jaya
- Abstract
Liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). It is the treatment of choice for immunocompetent patients in the Mediterranean region and the preferred drug for HIV/VL co-infection. Although there is a regional variation in the susceptibility of the parasite a total dose of 20 mg/kg is effective in immunocompetent patients. Randomized clinical trials of liposomal amphotericin B in the treatment and secondary prophylaxis of HIV-VL coinfected patients is urgently needed to optimize treatment in this subset. With the availability of Liposomal amphotericin B at a preferential pricing in the endemic areas, short course combination therapy can become a viable alternative.
- Publication
Journal of global infectious diseases, 2010, Vol 2, Issue 2, p159
- ISSN
0974-8245
- Publication type
Journal Article
- DOI
10.4103/0974-777X.62886